Global Pneumothorax Treatment Market Size Likely to Grow at a CAGR of 5.31% By 2034

Market Size and Growth

As per the Pneumothorax Treatment Market size analysis conducted by the CMI Team, the global Pneumothorax Treatment Market is expected to record a CAGR of 5.31% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 33 Billion. By 2034, the valuation is anticipated to reach USD 52.58 Billion.

Overview

According to industry experts at CMI, the implementation of new strategies and technologies by service providers presents lucrative opportunities for players in the Pneumothorax Treatment Market during the forecast period. Furthermore, the growing significance of organized retailing is expected to drive the future growth of the market.

Key Trends & Drivers

• Rise in Minimally Invasive Procedures: An increasing trend towards minimally invasive procedures for pneumothorax is changing with needle aspirations and small-bore catheter insertions. There are fewer hospitalizations, fewer procedural risks, and less pain for the patient compared to chest tube thoracostomy. Now, with advances in easy-to-use image-guided tools, these procedures can be carried out even in outpatient settings. Less invasive care, hence faster recovery followed by a cheaper alternative, is what patients want. As less invasive methods join the ranks of standard practice in several countries, it is translating to a more aggressive acceptance of advanced tools and devices, contributing to the overall increase in the pneumothorax treatment market.

• Adoption of Digital Thoracic Drainage Technologies: Digital thoracic drainage systems are transforming pneumothorax treatment by measuring air leaks, pleural pressure, and drainage output in real time. Through the facilitation of clinical decisions and the presence of better monitoring and fewer manual check errors, these machines allow for earlier weaning off of chest tubes and an earlier discharge. The hospitals are increasingly putting such unexplored systems to use in the ICUs and surgical recovery units for procuring better clinical outcomes and efficiency. The trend toward data-driven treatment is front and center in digital health. Therefore, smart drainage systems are a growing segment of the pneumothorax treatment market, particularly in developed healthcare systems.

• Increased Focus on Emergency and Trauma Care: The surge in the number of road accidents, along with falls and sports injuries globally, has resulted in the surge in the demand for well-equipped emergency and trauma care units that can receive and treat the pneumothorax quickly. The governments, along with the healthcare agencies, are investing in the trauma centers, ambulance services, and critical care infrastructure. In cases such as these, fast and effective treatment of pneumothorax increases the demand for portable imaging devices, pre-assembled chest tube kits, and rapid deployment drainage systems. With a great deal of attention being paid to improving trauma systems, the market for solutions to treat pneumothorax that are dependable, easy to use, and able to be implemented swiftly in the field is growing steadily.

• Growth of Point-of-Care Ultrasound (POCUS): In the emergency room and intensive care units, the point-of-care ultrasound has become an underlying tool for rapid bedside diagnosis of pneumothorax. It is a radiation-free, real-time imaging technique and allows doctors to detect air presence in the pleural space with high sensitivity. Due to the portability, affordability, and drive for POCUS training, this trend is gaining traction. More clinicians are being trained in the diagnostic aspects of ultrasound, thereby increasing the demand for compact and user-friendly ultrasound devices. This helps in faster diagnosis and treatment, in turn, better patient outcome, and championing the growth of both the diagnostics and interventional market segments.

• Shift Toward Outpatient and Home-Based Care: There has been a surge in the trend for managing stable or recurrent pneumothorax cases on an outpatient basis or through home care. As there has been an advancement in the portable chest drainage systems along with the remote monitoring devices, the patients can recuperate without the prolonged hospital stays. Several drivers behind this trend include controlling healthcare expenditures, patients opting to recover at home, and hospitals being overcrowded. Some manufacturers have developed compact devices that can be battery-operated and include remote-monitoring functions. Thus, as hospital systems from around the world move toward decentralizing care, the pneumothorax treatment market is growing to include home healthcare providers, which in turn expands the scope and application of treatment technologies.

• Integration of Artificial Intelligence and Smart Monitoring Technologies: AI and smart monitoring technologies are being integrated into the pneumothorax treatment tools, especially the digital drainage systems. A few AI algorithms analyze the drainage pattern, predict complications, make clinical decisions about chest tube removals, and so forth. Smart systems have the most impact in high-acuity environments such as ICUs, where a fine line exists between the timeliness and precision of information. Accordingly, as the healthcare domain leans toward predictive analytics and remote care, AI-powered tools are gaining more traction. This hampers the evolution of device technology and incites investments toward smart health care solutions, hence paving the road for high-tech growth and transformation of the pneumothorax treatment market.

Report Scope

SWOT Analysis

• Strengths: Pneumothorax, especially secondary spontaneous pneumothorax due to underlying lung diseases like COPD, asthma, and lung cancer, is a common condition. The shift towards less invasive procedures like Video-Assisted Thoracoscopic Surgery (VATS) and the use of smaller-bore chest tubes are key strengths. Public health campaigns and increasing awareness of respiratory health lead to earlier diagnosis and prompt treatment.

• Weakness: Despite general guidelines, there is often a lack of universally standardized treatment protocols across different healthcare settings and specialties, leading to variations in care and potentially suboptimal outcomes. Even after successful initial treatment, pneumothorax can recur, particularly spontaneous pneumothorax. While minimally invasive, procedures like chest tube insertion can still lead to complications such as pain, infection, hemorrhage, or malposition, impacting patient recovery and increasing healthcare costs.

• Opportunities: The increasing global burden of chronic respiratory diseases will continue to drive the incidence of secondary spontaneous pneumothorax, creating a sustained demand for treatment. The increasing adoption of telemedicine and remote patient monitoring technologies offers opportunities for prompt follow-up, early detection of recurrence, and improved adherence to treatment regimens, particularly for patients managed conservatively or with indwelling catheters.

• Threats: Inadequate or inconsistent reimbursement policies from insurance providers or government healthcare systems can limit access to advanced treatments and impact market growth. Global or regional economic instability can lead to reduced healthcare spending, impacting the procurement of new devices and technologies, especially in public health systems. Stringent regulatory approval processes for new medical devices can be time-consuming and expensive, delaying market entry for innovative products.

List of the prominent players in the Pneumothorax Treatment Market:

• Abbott
• Allergan
• Angiotech 
• ATMOS MedizinTechnik GmbH & Co. KG
• Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Medtronic
• Merck Sharp & Dohme Corp.
• Mylan N.V.
• Nobelpharma Co. Ltd
• Pfizer Inc.
• Smiths Group plc.
• Teleflex Incorporated
• Vygon
• Zebra Medical Vision Inc.
• Others

The Pneumothorax Treatment Market is segmented as follows:

By Type

• Primary Spontaneous
• Secondary Spontaneous
• Latrogenic
• Injury Related
• Catamenial

By Treatment

• Medication
• Antibiotics
• Benzodiazepines
• Opiate anesthetics
• Others

By Diagnosis

• Chest X-ray
• Computerized Tomography Scan
• Ultrasound
•  Physical Examination

By End-User

• Hospitals
• Clinics
• Ambulatory Distribution Channel

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America